Insights from experiences on antiplatelet drugs in stroke prevention: A review
- Authors: Signorelli S.S.; Platania I.; Tomasello S.D.; Mangiafico M.; Barcellona G.; Di Raimondo D.; Gaudio A.
- Publication year: 2020
- Type: Articolo in rivista
- Key words: Aspirin; Cilostazol; Clopidogrel; Combined drug therapy; Dipyridamole; Prevention; Stroke.
- OA Link: http://hdl.handle.net/10447/437635
Reduction of hazard risk of cerebral ischemic event (stroke, transient ischemic attack (TIA)) represents the hard point to be achieved from primary or secondary preventive strategy in the best clinical practice. However, results from clinical trials, recommendations, guidelines, systematic review, expert opinions, and meta-analysis debated on the optimal pharmacotherapy to achieve the objective. Aspirin and a number of antiplatelet agents, alone or in combination, have been considered from large trials focused on stroke prevention. The present review summarizes, discusses results from trials, and focuses on the benefits or disadvantages originating from antiplatelet drugs. Sections of the review were organized to show both benefits or consequences from antiplatelet pharmacotherapy. Conclusively, this review provides a potential synopsis on the most appropriate therapeutic approach for stroke prevention in clinical practice.